Table 1.
Characteristics of patients who survived versus those who died at 1 year.
| Variable | n (%) | P | ||
|---|---|---|---|---|
|
| ||||
| Total (n=126) | Alive (n=69) | Deceased (n=57) | ||
| Age (yr) | ||||
|
| ||||
| <55 | 11 (8.7) | 7 (10.1) | 4 (7.0) | 0.767 |
|
| ||||
| 55–74 | 76 (60.3) | 40 (58.0) | 36 (63.2) | |
|
| ||||
| ≥75 | 39 (31.0) | 22 (31.9) | 17 (29.8) | |
|
| ||||
| Gender | ||||
|
| ||||
| Female | 33 (26.2) | 19 (27.5) | 14 (24.6) | 0.705 |
|
| ||||
| Male | 93 (73.8) | 50 (72.5) | 43 (75.4) | |
|
| ||||
| Smoking status | ||||
|
| ||||
| Non-smoker/smoker/ex-smoker (<30 pack-years) | 51 (40.5) | 32 (46.4) | 19 (33.3) | 0.138 |
|
| ||||
| Smoker/ex-smoker (≥30 pack-years) | 75 (59.5) | 37 (53.6) | 38 (66.7) | |
|
| ||||
| Stage at diagnosis | ||||
|
| ||||
| 1 | 22 (17.5) | 22 (31.9) | 0 | <0.001 |
|
| ||||
| 2 | 11 (8.7) | 9 (13.0) | 2 (3.5) | |
|
| ||||
| 3 | 25 (19.8) | 11 (15.9) | 14 (24.6) | |
|
| ||||
| 4 | 68 (54.0) | 27 (39.1) | 41 (71.9) | |
|
| ||||
| ECOG status | ||||
|
| ||||
| 0 | 40 (31.7) | 29 (42.0) | 11 (19.3) | <0.001 |
|
| ||||
| 1 | 59 (46.8) | 35 (50.7) | 24 (42.1) | |
|
| ||||
| 2 | 15 (11.9) | 3 (4.3) | 12 (21.1) | |
|
| ||||
| 3 | 9 (7.1) | 0 | 9 (15.8) | |
|
| ||||
| 4 | 3 (2.4) | 2 (2.9) | 1 (1.8) | |
|
| ||||
| Histology | ||||
|
| ||||
| Adenocarcinoma | 83 (65.9) | 51 (73.9) | 32 (56.1) | 0.092 |
|
| ||||
| Squamous cell | 22 (17.5) | 11 (15.9) | 11 (19.3) | |
|
| ||||
| Non-small cell (others)a | 5 (4.0) | 2 (2.9) | 3 (5.3) | |
|
| ||||
| Small cell | 8 (6.3) | 1 (1.4) | 7 (12.3) | |
|
| ||||
| Othersb | 8 (6.3) | 4 (5.8) | 4 (7.0) | |
|
| ||||
| Mutations | ||||
|
| ||||
| ALK rearrangement | 2 (1.6) | 1 (1.4) | 1 (1.8) | 0.499 |
|
| ||||
| EGFR mutant | 34 (27.0) | 22 (31.9) | 12 (21.1) | |
|
| ||||
| ROS1 mutation | 1 (0.8) | 0 | 1 (1.8) | |
|
| ||||
| Driver mutations (%) | 29.3 | 33.3 | 24.6 | |
aRepresents adenosquamous carcinoma and undifferentiated non-small cell lung cancer. bRepresents lymphoepithelial-like carcinoma and carcinoid. ALK: anaplastic lymphoma kinase, ECOG: Eastern Cooperative Operative Group, EGFR: epidermal growth factor receptor, ROS1: receptor tyrosine kinase